MSLN and neoplasm: Our study showed that CAR-T derived exosomes can act as targeted carriers and deliver PTX to the local tumor origin to improve therapeutic efficacy, and this is attributed to the specific anti-MSLN scFv on the surface of exosomes to recognize and bind to MSLN, which was widely expressed in lung cancer.